Literature DB >> 14692037

The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer.

Michail S Lionakis1, Dimitrios P Kontoyiannis.   

Abstract

BACKGROUND: Invasive infections caused by molds other than Aspergillus, Fusarium, and Zygomycetes have been reported sporadically in patients with leukemia and allogeneic bone marrow transplantation (BMT). However, the significance of lower respiratory tract cultures that are positive for these saprophytic molds in an unselected population of patients with cancer remains unclear.
METHODS: The authors evaluated the significance of respiratory specimens positive for saprophytic molds in patients with cancer using the criteria set by the European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG). They included the diagnostic category of indeterminate pulmonary invasive mold infection (IMI) for cases that met the criteria for probable IMI but had other pathogens concomitantly isolated from the respiratory tract.
RESULTS: Eighty-five cases with at least 1 positive culture were identified in 79 patients. Two cases were proven IMI, 29 were indeterminate IMI, 5 were possible IMI, and 49 were no IMI. All 38 cases from patients with solid tumors represented colonization compared with only 11 of the 47 cases (23%) from high-risk patients (P < 0.0001). The positive predictive value (PPV) of cultures was 0% in patients with solid tumors and ranged from 4.3% to 76.6%, depending on the analytic model used, in high-risk patients with leukemia and recipients of BMT. Cultures positive for Scedosporium spp. had a higher PPV (9.1-100%) than did cultures positive for non- Scedosporium spp. (2.8- 69.4%).
CONCLUSIONS: Adjustments of the EORTC/MSG criteria may be required for the diagnosis of invasive infections caused by saprophytic molds, especially non-Scedosporium spp., in patients with cancer. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 14692037     DOI: 10.1002/cncr.11876

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Impact of zygomycosis on microbiology workload: a survey study in Spain.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Patricia Muñoz; Ignacio Gadea; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

Review 2.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 3.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 4.  Mononuclear phagocyte-mediated antifungal immunity: the role of chemotactic receptors and ligands.

Authors:  Muthulekha Swamydas; Timothy J Break; Michail S Lionakis
Journal:  Cell Mol Life Sci       Date:  2015-02-26       Impact factor: 9.261

5.  Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study.

Authors:  Fotis Sampsonas; Dimitrios P Kontoyiannis; Burton F Dickey; Scott E Evans
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

6.  Diagnosis from Tissue: Histology and Identification.

Authors:  Raquel Sabino; Nathan Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-05-13

7.  Coccidioides in lung transplant: case report.

Authors:  Mark Anthony Diaz; Maria Luisa Bayo; Francisco Alvarez; Salvador Alvarez
Journal:  BMJ Case Rep       Date:  2020-04-16

8.  Mycological Microscopic and Culture Examination of 400 Bronchoalveolar Lavage (BAL) Samples.

Authors:  H Zarrinfar; S Saber; P Kordbacheh; K Makimura; A Fata; M Geramishoar; H Mirhendi
Journal:  Iran J Public Health       Date:  2012-07-31       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.